FASN and neoplasm: Although metabolic interventions—such as glycolysis inhibitors, LDH inhibitors, FAO/FASN modulators, and agents targeting cholesterol metabolism—can restore immune activity in preclinical models, their translation is hindered by systemic toxicity, compensatory metabolic rewiring, and tumor-type–specific effects.